# Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study

> **NCT00526136** · PHASE2 · COMPLETED · sponsor: **Advanz Pharma** · enrollment: 735 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Placebo
- **DRUG:** Vernakalant (oral)

## Key facts

- **NCT ID:** NCT00526136
- **Lead sponsor:** Advanz Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** —
- **Final completion:** 2008-07
- **Target enrollment:** 735 (ACTUAL)
- **Last updated:** 2008-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00526136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00526136, "Vernakalant (Oral) Prevention of Atrial Fibrillation Recurrence Post-Conversion Study". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT00526136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*